The top pre-market NASDAQ Stock Market gainers are: LM Ericsson Telephone, Silicon Image, SAVVIS, ShoreTel, Regeneron Pharmaceuticals, Questcor Pharmaceuticals, and Vical. The top pre-market NASDAQ Stock Market losers are: MIPS Technologies, Broadcom, SuccessFactors, Entropic Communications, and RF Micro Devices.
LM Ericsson Telephone Co. (ERIC) stock jumped 10.58 percent to $14.53 in the pre-market trading, as its first quarter earnings surged on mobile broadband demand. Profit jumped 220 percent to 4.1 billion Swedish krona. On a per-share basis, earnings were 1.27 krona, higher than 0.39 krona last year. Excluding amortizations and write-downs of acquired intangibles, earnings per share rose 75 percent to 1.52 krona. Net sales for the quarter grew 17 percent to 53 billion krona. Global mobile penetration is 79 percent and total mobile subscriptions have reached 5.5 billion.
The company said its joint ventures Sony Ericsson contributed profit before tax of 0.1 billion krona, while ST-Ericsson's loss amounted to 0.6 billion krona. Further, the company said its sales in the first quarter were not impacted by the devastating earthquake and tsunami in Japan. However, it estimates delays in delivery of certain products, as its global supply chain of components is partly dependent on Japan. Effects will also depend on Japan's overall recovery but our best estimate is that we will be able to deliver the majority of these volumes before end of third quarter 2011, the company said in a statement.
Silicon Image, Inc. (SIMG) stock climbed 9.79 percent to $8.30 in the pre-market trading, as it guided second quarter revenue above Street view. The company expects second quarter revenue of $51 million to $53 million, while Street predicts $50.10 million. The company reported first quarter adjusted earnings of $2.43 million or 3 cents a share, compared to a loss of $3.63 million or 5 cents a share last year. Revenue rose to $49.0 million from $34.31 million. Analysts had expected profit of 1 cent a share on revenue of $47.95 million for the first quarter.
SAVVIS, Inc. (SVVS) stock advanced 8.66 percent to $39.14 in the pre-market trading, as CenturyLink Inc. (CTL) has agreed to buy SAVVIS in a cash and stock merger valued at $40 a share or a total of about $2.5 billion, plus net debt of around $0.7 billion which would be assumed or refinanced at close. SAVVIS stockholders would receive $30 per share in cash and $10 in common shares of CenturyLink, representing an 11 percent premium over SAVVIS' closing stock price as of the close of trading on April 26. The companies anticipate closing the transaction in the second half of 2011.
SAVVIS' first quarter loss narrowed to $1.8 million or $0.03 a share from $11.3 million or $0.21 a share last year. Earnings from continuing operations climbed to $16.5 million from $4.8 million last year. Revenue rose to $257 million from $216.6 million. Analysts had expected a loss of $0.11 a share on revenue of $256.08 million. The company still expects fiscal 2011 revenue of $1.03 billion to $1.06 billion, while Street predicts $1.06 billion.
ShoreTel, Inc. (SHOR) stock grew 8.59 percent to $9.99 in the pre-market trading. Adjusted profit for the third quarter was $602,000 or 1 cent a share, compared to a loss of $1.67 million or 4 cents a share last year. Revenue rose to $51.58 million from $37.03 million. Analysts had expected a loss of 2 cents a share on revenue of $49.78 million. The company expects fourth quarter revenue of $53 million to $56 million, while Street predicts $53.60 million. Adjusted gross margin is expected to be 67 percent to 68 percent.
Regeneron Pharmaceuticals, Inc. (REGN) stock grew 7.86 percent to $56.24 in the pre-market trading. Sanofi-Aventis and Regeneron Pharmaceuticals said that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP or aflibercept, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen, 5-fluorouracil, and irinotecan] versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.
Regeneron said the most frequent adverse events reported with ZALTRAP in combination with FOLFIRI were diarrhea, asthenia/fatigue, stomatitis and ulceration, nausea, infection, hypertension, gastrointestinal and abdominal pains, vomiting, decreased appetite, decreased weight, epistaxis, alopecia, and dysphonia. Based upon these positive findings, we and Sanofi-Aventis plan to submit regulatory applications for marketing approval to the U.S. Food and Drug Administration and the European Medicines Agency in the second half of the year, said George Yancopoulos, Chief Scientific Officer of Regeneron and President of Regeneron Research Laboratories.
Questcor Pharmaceuticals, Inc. (QCOR) stock gained 6.83 percent to $20.50 in the pre-market trading, as its first quarter earnings exceeded Street view. Adjusted profit was $12.8 million or $0.20 per share, up from $8.6 million or $0.14 per share last year. Sales rose to $36.83 million from $26.24 million. Analysts had expected profit of $0.16 per share on revenue of $36.03 million.
Vical Inc. (VICL) stock increased 2.71 percent to $3.79 in the pre-market trading, as it reported encouraging H1N1 pandemic influenza vaccine phase 1 results. The company said more than half of the subjects in the Phase 1 trial of the company's Vaxfectin-formulated vaccine for H1N1 pandemic influenza generated neutralizing antibodies of the type expected to provide protection against the disease. The vaccine was well-tolerated.
The encouraging results of our Phase 1 clinical testing of our H1N1 vaccine, coupled with the successful Phase 1 clinical testing of our H5N1 avian-origin influenza vaccine, provide further validation for both our vaccine platform and our Vaxfectin adjuvant. Through our collaboration with NMRC, we are working toward establishing an emerging disease vaccine platform to provide rapid protection against novel pathogens, initially for military personnel and eventually for the broader population, said Larry Smith, Vical's Vice President of Vaccine Research.
MIPS Technologies Inc. (MIPS) stock plunged 14.79 percent to $9.10 in the pre-market trading, as its third quarter earnings and revenue missed Street view. Adjusted profit was $4.7 million or 9 cents a share, up from $3.9 million or 8 cents a share last year. Revenue rose to $20.1 million from $17.5 million. Analysts had expected profit of 10 cents a share on revenue of $21.70 million. In the conference call, the company said it now expects full-year revenues of $84 million to $86 million, lower than its projection of $85 million to $88 million. Royalty revenue is expected to drop 8 percent to 10 percent in the fourth quarter, on lower volumes of shipping. Street analysts predict revenue of $87.21 million for full year 2011.
Broadcom Corp. (BRCM) stock fell 8.07 percent to $37.15 in the pre-market trading, as it guided second quarter revenue below Street view. The company expects second quarter revenue of $1.75 billion to $1.85 billion, with margins anticipated to improve 50 basis points from the first quarter. Street analysts predict revenue of $1.9 billion.
Broadcom reported first quarter earnings of $228 million or 40 cents a share, compared to $210 million or 40 cents a share last year. Results for the quarter include impairment costs of $9 million. Revenue rose to $1.82 billion from $1.46 billion. Analysts had expected profit of 59 cents a share on revenue of $1.81 billion.
SuccessFactors, Inc. (SFSF) stock tumbled 7.65 percent to $37.19 in the pre-market trading. The company expects second quarter adjusted earnings to be breakeven per share and adjusted revenue of $69 million to $70 million, while Street predicts breakeven per share on revenue of $65.62 million. For the full year 2011, the company continues to expect adjusted earnings to be breakeven per share. The company raised 2011 adjusted revenue outlook to range of $275 million to $280 million from previous range of $265 million to $270 million. Street analysts predict profit of $0.03 per share on revenue of $268.80 million for the year 2011.
SuccessFactors reported first quarter adjusted earnings of $763,000 or $0.01 per share, down from $1.3 million or $0.02 per share last year. Revenue grew 51 percent to $67.6 million, while adjusted revenue grew 52 percent to $68 million. Analysts had expected breakeven a share on revenue of $63.33 million.
Separately, SuccessFactors said it agreed to buy Plateau, the leading learning management system, a Next Generation Portal technology, and CaaS (Content as a Service). SuccessFactors will pay $145 million in cash plus $145 million in stock, about $15 million is for employee stock options and RSUs, for Plateau. The acquisition is currently expected to close during summer 2011. After the deal closes, Plateau's SaaS based LMS will be integrated directly into SuccessFactors' BizX suite.
Entropic Communications, Inc. (ENTR) stock slid 5.20 percent to $8.02 in the pre-market trading. Adjusted profit for the first quarter was $19.6 million or $0.22 a share, up from $4.4 million or $0.06 a share last year. Revenue rose to $71.5 million from $37.5 million. Analysts had expected profit of $0.21 a share on revenue of $71.34 million.
RF Micro Devices Inc. (RFMD) stock decreased 4.27 percent to $6.05 in the pre-market trading. Adjusted profit for the fourth quarter was $21.70 million or $0.08 a share, down from $43.8 million or $0.16 a share last year. Revenue fell to $213.3 million from $260.8 million. Analysts had expected profit of $0.08 a share on revenue of $213.91 million. The company expects first-quarter revenue to be flat to down 5 percent sequentially, as 8 percent to 12 percent growth in RFMD's core business is offset by declining sales of legacy products. Street analysts predict revenue of $226.92 million for the first quarter.